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Abstract:  Sickle  cell  disease  (SCD)  is  characterized  by  recurrent  vaso
Patients  with  SCD  have  impaired  immunity  and  are  thus  predispose  to  infections.  The  vast 
majority of SCD patients live in underdeveloped nations with high prevalence and transmission 
rates of infections. This makes the SCD patients
VOC. We reviewed the role of infection in the pathogenesis of VOC, taking into consideration all 
potential  mechanisms  from  previous  studies  and  hypothetical  perspectives.  The  potential 
mechanisms  through  which  infections  may  lead  to  VOC  involve  several  pathological  changes 
including  pneumonitis,  pyrexia,  acute  phase  reaction,  hypercoagulability,  neutrophilia, 
eosinophilia,  thrombocytosis,  bronchospasm,  red  cell  cytopathic  and  membrane  changes,  auto
antibodies mediated red cell agglutination and opsonization, diarrhoea and vomiting, which may 
act singly or in concert to cause red cell sickling. These changes can induce sickling directly or 
indirectly through their adverse effects on Hb oxygenation and polymer
viscosity, red cell metabolism, procoagulant activation, intercellular adherence and aggregation, 
culminating in VOC. There is therefore the need to ameliorate the burden of infection on SCD 
through immunization, prophylactic and 
vector control in communities with high prevalence of SCD.  
 
Introduction:  Haemoglobin  S  (HbS)  is  a  structural
variant of the normal haemoglobin (HbA) and is due to 
a  genetic  mutation  in  the  β  globin  gene  where 
thymidine replaced adenine resulting in the substitution 
of glutamic acid by valine in position 6 of the 
chain.
1 This substitution caused a significant alteration 
in the physico-chemical properties of HbS, which has a 
reduced  solubility  in  the  deoxygenated  state.
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Sickle  cell  disease  (SCD)  is  characterized  by  recurrent  vaso-occlusive  crisis  (VOC). 
Patients  with  SCD  have  impaired  immunity  and  are  thus  predispose  to  infections.  The  vast 
majority of SCD patients live in underdeveloped nations with high prevalence and transmission 
rates of infections. This makes the SCD patients prone to infections, which frequently precipitate 
VOC. We reviewed the role of infection in the pathogenesis of VOC, taking into consideration all 
potential  mechanisms  from  previous  studies  and  hypothetical  perspectives.  The  potential 
hich  infections  may  lead  to  VOC  involve  several  pathological  changes 
including  pneumonitis,  pyrexia,  acute  phase  reaction,  hypercoagulability,  neutrophilia, 
eosinophilia,  thrombocytosis,  bronchospasm,  red  cell  cytopathic  and  membrane  changes,  auto
es mediated red cell agglutination and opsonization, diarrhoea and vomiting, which may 
act singly or in concert to cause red cell sickling. These changes can induce sickling directly or 
indirectly through their adverse effects on Hb oxygenation and polymerization, hydration, blood 
viscosity, red cell metabolism, procoagulant activation, intercellular adherence and aggregation, 
culminating in VOC. There is therefore the need to ameliorate the burden of infection on SCD 
through immunization, prophylactic and therapeutic use of antimicrobials, barrier protection and 
vector control in communities with high prevalence of SCD.   
Haemoglobin  S  (HbS)  is  a  structural 
variant of the normal haemoglobin (HbA) and is due to 
  globin  gene  where 
thymidine replaced adenine resulting in the substitution 
of glutamic acid by valine in position 6 of the β-globin 
This substitution caused a significant alteration 
chemical properties of HbS, which has a 
reduced  solubility  in  the  deoxygenated  state.
2  The 
sickle  β-gene  mutation  confers  relative  protection 
against  falciparum  malaria  among  individuals  with
sickle  cell  trait  (SCT).
3,4  Consequently,  through  the 
process of natural  selection, children  with SCT  have 
relative higher survival advantage in malaria endemic 
zones.
3,4 This phenomenon is responsible for the high 
prevalence  of  SCT  in  the  malaria  endemic
Africa where up to 10-40% of indigenous populations 
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occlusive  crisis  (VOC). 
Patients  with  SCD  have  impaired  immunity  and  are  thus  predispose  to  infections.  The  vast 
majority of SCD patients live in underdeveloped nations with high prevalence and transmission 
prone to infections, which frequently precipitate 
VOC. We reviewed the role of infection in the pathogenesis of VOC, taking into consideration all 
potential  mechanisms  from  previous  studies  and  hypothetical  perspectives.  The  potential 
hich  infections  may  lead  to  VOC  involve  several  pathological  changes 
including  pneumonitis,  pyrexia,  acute  phase  reaction,  hypercoagulability,  neutrophilia, 
eosinophilia,  thrombocytosis,  bronchospasm,  red  cell  cytopathic  and  membrane  changes,  auto-
es mediated red cell agglutination and opsonization, diarrhoea and vomiting, which may 
act singly or in concert to cause red cell sickling. These changes can induce sickling directly or 
ization, hydration, blood 
viscosity, red cell metabolism, procoagulant activation, intercellular adherence and aggregation, 
culminating in VOC. There is therefore the need to ameliorate the burden of infection on SCD 
therapeutic use of antimicrobials, barrier protection and 
gene  mutation  confers  relative  protection 
against  falciparum  malaria  among  individuals  with 
Consequently,  through  the 
process of natural selection,  children with SCT have 
relative higher survival advantage in malaria endemic 
This phenomenon is responsible for the high 
prevalence  of  SCT  in  the  malaria  endemic  zones  of 
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have  SCT.
5  Therefore,  malaria  is  the  single  most 
important infective driver for the perpetuation of SCT, 
which,  through  carrier  inter-marriages,  had  led  to  a 
high  prevalence  of  sickle  cell  disease  in  black 
Africa.
1,3,5 While homozygous HbS disease (sickle cell 
anemia) is the most common type of sickle cell disease 
(SCD), less common types of SCD arise as a result of 
double heterozygosity between HbS gene and different 
β-globin  gene  mutations  such  as  haemoglobin  C 
(HbSC)  or  β-thalassaemia  (HbSβthal)  that  share  a 
similar  basic  pathophysiology.
1,2,6  The  clinical 
presentation of SCD is due to vaso-occlusive episodes 
resulting  from  polymerization  of  deoxygenated  Hb-S 
leading  to  the  formation  of  sickled  red  cells.
2  The 
clinical  course  of  SCD  is  typically  characterized  by 
variable  periods  of  steady  state  that  is  periodically 
interrupted by painful vaso-occlusive crisis, which can 
be triggered by psychological, physical and infective 
factors.
7,8 
Patients with SCD have increased susceptibility to 
infections,  which  is  partly  due  to  autosplenectomy 
resulting from recurrent vaso-occlusive infarcts within 
the  spleen.
9  Several  other factors  that  predispose  the 
SCD  patients  to  infections  have  also  been  reported, 
which include abnormalities of opsonization, antibody 
production,  the  alternate  complement  pathway, 
leukocyte functions and cell-mediated immunity.
10,11,12 
Consequently,    life-threatening  infections  are  major 
causes  of  morbidity  and  mortality  in  patients  with 
SCD. The range of immune abnormalities in SCD to a 
large extent determines the pattern of microbiological 
susceptibility in affected patients. Thus hyposplenism 
predisposes  to  severe  infections  with  malaria  and 
encapsulated  organisms  including Haemophilus 
influenza  and  Streptococcus  pneumoniae,  while  low 
serum  IgM  levels,  impaired  opsonization,  and 
abnormality  of  complement  pathway  would  further 
increase  susceptibility  to  other  common  infectious 
agents,  including Mycoplasma  pneumoniae, 
Salmonella  typhimurium,   Staphylococcus 
aureus, and Escherichia  coli.
9,13  In  addition  to 
immunological  dysfunction,  another  factor  that 
increases susceptibility to bacterial infection in patients 
with SCD is recurrent  tissue  infarcts.  Tissue  infarcts 
provide  potential  primary  foci  for  infections  that  are 
easily propagated within the context of a pre-existing 
immunological  dysfunction  associated  with  the 
background  SCD.
14  Chronic  haemolysis  and 
vasculopathy  are  major  manifestations  of  SCD.
15 
Hence, another factor that increases the susceptibility 
of  SCD  patients  to  infection  is  chronic  transfusion 
therapy,  which  has  gained  prominence  in  the 
prevention  and  management  of  stroke,  priapism, 
pulmonary  hypertension,  acute  chest  syndrome  and 
chronic renal failure in affected patients in whom iron 
overload  has  become  increasingly  common.
16 
However, it should be appreciated that  iron overload 
in SCD patients will raise the risk of infections with 
iron-dependent bacteria such Yersinia species, thereby 
amplifying the pre-existing risk of infection due to the 
background immunodeficiency associated with SCD.
17 
Precious  studies  had  demonstrated  that  malaria, 
bacterial and other forms of infections are associated 
with  crises,  exacerbation  of    morbidity  and  poor 
survival among patients with SCD.
8,18 
Red  cell  sickling  is  a  pathognomonic  feature  of 
SCD. Red cells of SCD patients go through repeated 
cycles  of  deoxygenation  (in  the  tissues)  and  re-
oxygenation  (in  the  lungs).  This  sequence  of  events 
creates a dynamic scenario of sickling and un-sickling 
until the cell membrane sustains a significant degree of 
damage,  which  eventually  leads  to  the  formation  of 
irreversibly  sickled  cells  that  are  invariably 
haemolysed.
19 Hence SCD is associated with chronic 
haemolysis,  which  is  consistently  accompanied  by 
reticulocytosis. Sickle reticulocytes had been shown to 
abundantly  express  the  alpha-4  beta-1  integrin 
complex,  which  binds  endothelial  VCAM-1 
receptors.
20 Therefore, sickle reticulocytes endothelial 
adhesion  is  thought  to  play  a  primary  role  in  the 
initiation of vascular occlusion in the pathophysiology 
of VOC, which is subsequently amplified by continued 
red cell sickling and piling of irreversibly sickled cells 
due to hypoxia and/or other sickling-inducing factors.
21 
However,  red cell sickling is more prominent during 
crisis,  but continuous  sickling  does occur  at  a lower 
rate even in the steady state.
22 Therefore, any causative 
factor  for  VOC  must  necessarily  be  able  to 
significantly    increase  the  rate  of  sickling  and/or 
decrease  the  rate  of  un-sickling  (i.e.  reversal  of 
reversibly  sickled  cells  to  discocytes)  to  a  level  that 
would  significantly  shift  the  clinical  status  of  the 
patient from steady state  to crisis.  
In this report we reviewed the potential mechanisms 
by which infection can contribute to the pathogenesis 
of  VOC  in  patients  with  SCD.  These  mechanisms 
involve  pathological  changes  including  pneumonitis, 
pyrexia,  acute  phase  reaction,  hypercoagulability, 
neutrophilia,  eosinophilia,  thrombocytosis, 
bronchospasm,  red  cell  cytopathic  and  membrane 
changes,  auto-antibodies  mediated  red  cell 
agglutination  and  opsonization,  diarrhoea  and 
vomiting,  that  may  act singly or in concert  to  cause 
increased  sickling  and/or  decrease  un-sickling  and 
potentially culminate in VOC as outlined in Table 1. 
 
Pneumonic  and  Inflammatory  Changes  with 
Impaired  Gaseous  Exchange:  Respiratory  tract 
infections in patients with SCD vary in severity from 
mild upper tract infection to moderately severe  
 Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
Table 1: Possible Mechanisms for VOC in SCD Patients with Infections 
Pathological Processes  Common Causative 
Pathogens  Possible Mechanisms Leading to Red Cell Sickling & VOC 
Chest Infection/Pneumonic 
consolidations/Acute chest 
syndrome. 
Acute bacterial.  
Mycoplasma. 
Tuberculosis. 
•  Inflammatory infiltrates leading to impaired oxygenation. 
•  Peripheral blood hypoxia generates more sickled cells.  
•  Decreased conversion of  deoxy-HbS to oxy-HbS. 
•  Accumulation of deoxy-HbS. 
•  Failure to convert reversibly sickled cells to discocytes. 
Acute phase reaction.  Any infection. 
•  Increased plasma viscosity. 
•  Decreased capillary flow/stasis. 
•  Increased production of deoxy-HbS. 
Pyrexia, Diarrhoea, 
Vomiting. 
Any infection. 
Especially 
enteropathogens. 
•  Excess water loss leads to dehydration. 
•  Dehydration leads to high plasma viscosity and osmolality, stasis, 
increased production of deoxy-HbS. 
•  Dehydration leads to high MCHC. 
•  High MCHC increases rate of red cell sickling 
•  High temperature increases rate of HbS polymerization and sickling. 
Neutrophilia.  Pyogenic bacteria. 
Tuberculosis. 
•  Increased blood viscosity/stasis lead to increased production of deoxy-
HbS. 
•  Increased oxygen consumption by activated neutrophils lead to 
increased production of deoxy-HbS. 
•  Activated neutrophils generate more free radicals, decrease 
antioxidants and predispose to red cell sickling. 
•  Increased adhesion of neutrophils to sickled cells and vascular 
endothelium lead to vascular occlusion.  
Thrombocytosis. 
Most infections, 
except malaria and 
some viruses.  
•  Increased blood viscosity/stasis lead to increased production of deoxy-
HbS. 
•  Platelets activated by endothelial damage leading to vascular 
occlusion. 
Erythrocytopathic effect of 
malaria. 
Plasmodium 
falciparum. 
•  Malaria invasion of red cell induces massive sickling and KAHRP 
knobs formation on red cell membrane. 
•  Sickling induce formation of ICAM-1 and VCAM-1 on vascular 
endothelial membrane. 
•  Formation of KAHRP knobs on red cells enhance adhesion of infected 
sickled red cells to endothelium and promotes vascular occlusion. 
•  KAHRP knobs act synergistically with endothelial ICAM-1 and 
VCAM-1 receptors to enhance sickle cell adherence to endothelium. 
Loffler’s syndrome.  Ascariasis and 
Ancylostomiasis. 
•  Migrating larvae/eosinophilic infiltrates in the lungs and bronchospasm 
leading  to impaired oxygenation. 
•  Peripheral blood hypoxia generates more sickled cells.  
•  Decreased conversion of  deoxy-HbS to oxy-HbS. 
•  Accumulation of deoxy-HbS. 
•  Failure to convert reversibly sickled cells to discocytes. 
•  Peripheral eosinophilia with activated eosinophils adhering to 
endothelium and causing vascular occlusion. 
Tropical pulmonary 
eosinophilia syndrome.  Filariasis. 
•  Microfilarial/eosinophilic infiltrates in the lungs and bronchospasm 
leading  to impaired oxygenation. 
•  Peripheral blood hypoxia generates more sickled cells.  
•  Decreased conversion of  deoxy-HbS to oxy-HbS. 
•  Accumulation of deoxy-HbS. 
•  Failure to convert reversibly sickled cells to discocytes. 
•  Peripheral eosinophilia with activated eosinophils adhering to 
endothelium and causing vascular occlusion. 
Red cell autoantibody 
formation. 
Mycoplasma 
pneumoniae. 
•  Auto-antibodies cause red cell agglutinations & stasis, increased 
production of deoxy-HbS and sickling. 
•  Auto-antibodies cause sickled red cell opsonization. 
•  Increased adhesion between opsonized sickled red cell and neutrophil 
via Fc & C3 receptors, leading to vascular occlusion. 
KAHRP=Knob Associated Histidine Rich Proteins. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
 
uncomplicated  pneumonia  that  can  be  managed  with 
appropriate  antibiotics.  Nonetheless,  every  case  of 
respiratory  tract  infection  must  be  monitored  closely 
because of the potential risk of acute chest syndrome 
(ACS),  which  is  a  serious  and  potentially  fatal 
complication.
23  The  commonest  cause of the  ACS  is 
acute  pulmonary  infection  by  a  community-acquired 
pathogens,  which  incite  pneumonic  changes  due  to 
excessive inflammatory response to what often should 
have  been  a  mild  respiratory  infection  in  patients 
without  SCD. 
23  The  susceptibility  of  patients  with 
SCD  to  develop  excessive  pulmonary  inflammatory 
response and infiltrates was corroborated by previous 
studies,  which  had  shown  that  transgenic  mice  with 
HbS were highly susceptible to inflammatory triggers 
such as endotoxins and environmental hypoxia with the 
development of pulmonary tissue injury at doses that 
would  not  adversely  affect  wild-type  non-transgenic 
mice.
24,25  Therefore,  it  can  be  deduced  that  SCD 
confers  upon  its  sufferers  special  propensity  for 
exaggerated pulmonary inflammatory response that can 
transform apparently simple acute chest infections to 
ACS.  ACS  is  associated  with  intense  alveolar 
consolidation and pulmonary sequestration of sickled 
red cells, resulting in lung injury and impaired gaseous 
exchange  across  the  alveolar  membrane.
23  These 
pulmonary changes would predictably lead to a fall in 
PaO2, generalized hypoxia, increased red cell sickling, 
decreased pulmonary conversion of deoxy-HbS to oxy-
HbS,  failure  of  reversal  of  sickled  red  cells  to 
discocytes,  piling  of  sickled  cells  and  VOC.  Hence, 
ACS  can  be  rapidly  progressive  and  fatal  unless 
managed with blood gas monitors, oxygen therapy and 
exchange blood transfusion in addition to appropriate 
antibiotics administration.
26 
It  should  be  appreciated  that  chronic  chest 
infections can also interfere with pulmonary function 
and intensify red cell sickling in SCD patients. This is 
particularly  important  because  the  vast  majority  of 
SCD patients live in underdeveloped nations with high 
prevalence  and  transmission  rates  of  tuberculosis 
within the general populations.
27 Patients with SCD are 
at  high  risk  of  contracting  tuberculosis  infection  in 
view  of  their  impaired  immunity.
10,11,12,27  Previous 
study had shown that pulmonary tuberculosis in SCD 
patients was associated with increased red cell sickling, 
which was a reflection of impaired pulmonary function 
and hypoxia.
28 Hence, pulmonary dysfunction due to 
chronic  chest  infections  would  increase  the  risk  of 
VOC in patients with SCD.
28 
It  is  therefore  imperative  that  SCD  patients  with 
acute or chronic infections of the lungs must be closely 
monitored with blood gas analyzers so as to detect and 
correct hypoxia  and its deleterious effect on red  cell 
sickling.  
 
Acute Phase Reaction: Vascular occlusion and tissue 
necrosis, though more pronounced during VOC, also 
occur at lower  rate during the steady state.
22 Earlier 
studies  had  revealed  that  re-perfusion  of  necrotic 
tissues resulted in the generation  of  oxygen radicals, 
leading  to  inflammatory  endothelial  and  tissue 
injury.
29,30 Many inflammatory markers of acute phase 
reaction are elevated in SCD patients even in steady 
state,  including  C-reactive  protein,  TNF-alpha,  and 
interleukin-1  and  -8,  in  addition  to  the  mediators  of 
endothelial  activation  such  as  VCAM-1  and 
endothelin-1.
31  Continuous  inflammation  and 
generation  of  oxygen  radicals  would  lead  to  a  high 
utilization of antioxidant reserves in patients with SCD. 
Consequently,  some  studies  had  shown  that  patients 
with SCD in steady state had significantly reduced total 
antioxidant status.
32 Further more, it had been revealed 
that the risk of developing VOC correlated negatively 
with the levels of total antioxidant status, suggesting 
that  inflammation  associated  oxidative  stress 
contributes  to  the  pathophysiology  of  VOC.
32  These 
reports  clearly under  scored the fact that  SCD is by 
itself a state of systemic chronic inflammatory disorder 
even  in  the  absence  of  infection.  However,  the 
acquisition  of  infection  by  patients  with  SCD  would 
certainly  aggravate  the  background  inflammatory 
response  and  generate  more  oxygen  radicals  through 
oxidative  respiratory  bursts  of  activated  neutrophils 
and phagocytes, which will cause further depletion of 
antioxidant reserves and precipitate VOC.
29,30,32,33 It is 
therefore  reasonable  to  continue  to  investigate  the 
potential  usefulness  of  antioxidants  in  mitigating  red 
cell  sickling,  prevention  and  attenuation  of  VOC  in 
SCD patients with infection.
34 Further more, it should 
be  appreciated  that  iron  overload,  in  addition  to 
predisposing to infection, is associated with increased 
generation of oxygen free radicals that would deplete 
antioxidant stores and aggravate inflammatory cellular 
injuries  in  patients  with  SCD.
35  Therefore,  chronic 
transfusion therapy in SCD must be used judiciously 
with the complement of iron chelation therapy in order 
to mitigate the deleterious effect of iron overload.
36 
Continuing  infection  would  trigger  humoral 
response  with  immunoglobulin  production  while 
ensuring a sustained elevation of plasma levels of acute 
phase reactants including fibrinogen, FVIII, vWF and 
other  coagulation  factors  that  would  raise  plasma 
viscosity  and  induce  hypercoagulability.
37  Sustained 
hyperviscosity  would  result  in  stasis  and  increased 
production  of  deoxy-HbS  with tendency  towards  red 
cell  sickling,  while  hypercoagulability  would  lead  to Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
intra-vascular fibrin deposition thereby reinforcing the 
vascular  occlusion.
38  Yet  other  inflammatory  makers 
such  as  VCAM-1  and  ICAM-1  induce  adhesion  of 
sickled red cells onto the endothelium, which further 
jeopardizes vascular patency.
39 
It  is  therefore  obvious  that  changes  in  plasma 
proteins due to infection and inflammatory acute phase 
reaction  can  adversely  affect  rheology,  coagulability, 
intercellular adhesions and antioxidant reserves, all of 
which significantly raise the risk of red cell sickling 
and  VOC  in  patients  with  SCD.  Hence,  it  is  of 
paramount importance that infections in SCD must be 
treated at the outset without delay in order to preempt 
the  intensity  of  acute  phase  reaction  and  their  vaso-
occlusive effects.   
 
Pyrexia, Diarrhoea, Vomiting: Pyrexia could arise as 
a result of the pyrogenic effects of some inflammatory 
acute phase reactants such as TNF-alpha (endogenous 
pyrogens)  or  as  a  result  of  the  effect  of  exogenous 
pyrogens  associated  the  infecting  micro-organisms.
40 
In  addition  to  pyrexia,  enteropathogenic  organisms 
such as E Coli, Salmonella and Shigella species could 
cause  severe  diarrhea  and  vomiting.
41  Pyrexia  is 
invariably  associated  with  increased  rate  of 
perspiration and water loss via the skin, while diarrhea 
and  vomiting  would  result  in  gastro-intestinal  water 
loss.  The  combined  effect  of  pyrexia,  diarrhea  and 
vomiting  would  lead  to  dehydration,  hyperviscosity 
and  stasis.  Patients  with  SCD  are  particularly 
susceptible  to  dehydration  due  to  their  inability  to 
conserve water as a result of hyposthenuria.
42 Hence, 
through  the  concerted  effect  of  acute  phase  reaction 
and dehydration, leading to hyperviscosity and stasis, 
infection can be an efficient trigger of VOC in patients 
with  SCD.  In  addition  to  its  role  in  causing 
dehydration,  pyrexia  is  particularly  deleterious  in 
patients with SCD as previous studies had shown that 
rates of HbS polymerization and red cell sickling were 
faster  at  higher  temperatures.
43,44  Further  more, 
sustained uncorrected plasma dehydration would lead 
to red cell dehydration and elevation of MCHC, which 
is an important promoter of HbS polymerization and 
red cell sickling.
43,44 
It can therefore be surmised that the triple concert 
between pyrexia, diarrhoea and vomiting in a patient 
with  SCD  would  result  in  dehydration  and  impaired 
rheology,  which  will  cause  stasis  and  increased 
production of deoxy-HbS, the polymerization of which 
is  subsequently  enhanced  by  high  temperature  and 
rising MCHC eventually leading to sickling and VOC. 
This scenario  under  scores  the indispensible  roles  of 
adequate  intravenous  hydration  and  antipyretics,  in 
addition  to  antibiotics,  in    the  management  of  SCD 
patients with infections. 
 
Neutrophilia:  Neutrophilia  is  a  useful  marker  of 
infection in many clinical settings. However, it must be 
appreciated  that  modest  neutrophilia  is  a  common 
feature of SCD even in steady state in the absence of 
infection. Steady state neutrophilia was thought to be 
due to redistribution of neutrophils from marginal to 
circulating  pool.
45  Nonetheless,  the  prevalence  and 
intensity  of  neutrophilia  are  higher  in  SCD  patients 
with  bacterial  infections  in  comparison  to  those 
without  infection.
28,46  In  our  experience,  the 
neutrophilia in SCD patients with bacterial infections 
was usually accompanied by eosinopenia, which was 
usually  absent    in  non-infected  patients.
28,46 
Eosinopenia  of infection  is mediated by inflammatory 
response  associated  with  the  release  of  adrenal 
corticosteroids,  epinephrine  and  chemotactic  factors, 
which  lead  to  rapid  peripheral  sequestration  of 
eosinophils  and  their  migration  into  inflammatory 
sites.
47,48 Neutrophilia in SCD patients with infection 
would have far reaching consequences with respect to 
the  pathophysiology  of  sickling.  Firstly,  as  earlier 
mentioned, infectious activation of neutrophils would 
trigger  respiratory  bursts  leading  to  generation  of 
oxygen free radicals, depletion of antioxidant reserves 
and  predispose  to  sickling  and  VOC.
32,33  Secondly, 
increased number  of  circulating  activated  neutrophils 
would lead to greater oxygen consumption, which may 
cause  hypoxia,  resulting  in  sickling  and  VOC.
33,49 
Thirdly, neutrophilia would aggravate blood viscosity, 
which will lead to stasis and increased production of 
deoxy-HbS  and  red  cell  sickling.
50  And  fourthly, 
neutrophils  in  SCD  exhibit  increased  adherence  to 
endothelium  and  sickle  red  cells,  hence,  neutrophilia 
would  promote  vascular  occlusion  in  patients  with 
SCD.
51,52 
It is therefore not surprising that the  beneficial role 
of hydroxyurea in the management of SCD is partly 
related to its ability to cause modest reduction in the 
number  of  circulating  neutrophils,  thus 
counterbalancing their adverse role in the pathogenesis 
of vascular occlusion.
53 
 
Thrombocytosis:  Thrombocytosis  is  a  common 
finding in patients with SCD even in steady state in the 
absence  of  any  infection.  This  phenomenon  was 
attributed to the background haemolytic anaemia and 
autosplenectomy.
22,27,54  However,  previous  studies 
revealed that SCD patients with infections had higher 
platelet  count  and  more  intense  thrombocytosis  in 
comparison to their counterparts without infections.
28 
This  finding  was  interpreted  to  be  a  reflection  of 
additional  effect  of  reactive  inflammatory  changes 
associated  with  infection.
28,55  In  similarity  to 
neutrophilia, thrombocytosis can raise blood viscosity Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
and  predispose  to  stasis,  sickling  and  VOC.
50  The 
hallmark of VOC is tissue necrosis, which is associated 
with  vascular  endothelial  damage  and 
dysfunction.
56,57,58  Endothelial  damage  leads  to 
exposure  of  subendothelial  structures,  including  sub-
endothelial  microfibrils  and  collagen,  both  of  which 
cause  platelet  activation  and  aggregation resulting  in 
vascular occlusion.
56,57,58 
It can therefore be surmised that any infections in 
patients  with  SCD  would  lead  to  intensification  of 
thrombocytosis  and  increase  the  risk  of  VOC.  It  is 
within  the  context  of  these  findings  that  some 
researchers  are  exploring  the  possible  role  of  anti-
platelet  agents  in  mitigating  vaso-occlusive 
complications of SCD.
59 
 
Erythrocytopathic    Effect    of  Malaria:  The  SCT 
offers  relative  protection  against  malaria  infection.
60 
The mechanism of protection was thought to be largely 
related to innate factors such as the reduced ability of 
Plasmodium falciparum parasites to grow and multiply 
in SCT red cells.
60 Recent studies have suggested  that 
protection against malaria in SCT might also involve 
the  accelerated  acquisition  of  malaria-specific 
immunity  within  the  context  of  the  normal  immune 
response in persons with SCT.
61,62 In contradistinction, 
patients with SCD have impaired immune response and 
are  prone    to  develop  infections  including  severe 
malaria, which was reported to be the most common 
trigger of VOC in patients living in malaria endemic 
countries.
18,63  Malaria  parasites  directly  invade  and 
replicate within red cells during the erythrocytic phase 
of  its  lifecycle.  Infected  red  cells  would  invariably 
sickle as a result of metabolic changes  induced by the 
invading parasites.
64 The sickled red cells subsequently 
adhere  to  vascular  endothelium  via  ICAM-1  and 
VCAM-1 receptors.
39 The potency of malaria infection 
in inducing VOC may be related to its special ability to 
deform the membrane of infected red cells leading to 
the formation of histidine rich protein knobs.
65 These 
knobs  confer  upon  malaria  infected  sickled  red  cells 
the  affinity  for  vascular  endothelium  leading  to 
adhesion.
65 Therefore, the malaria infected sickled red 
cell has double predilection for the endothelium due to 
expression  of  cytoadhesion molecules  (VCAM-1  and 
ICAM-1)  on  the  endothelium  and  due  to  the 
cytoadherent  effect  of  the  histidine  rich  protein 
domains  in  the  knobs  on  the  red  cell  membrane.
39,65 
This  double  predilection  makes  the  malaria  infected 
sickled cell extremely adherent to the endothelium. We 
therefore  deduce  that  the  dual  ability  of  malaria  to 
directly  induce  sickling  of  red  cells  (by  red  cell 
invasion) and potentiate their adherence to endothelium 
(by Knob formation) are the principal factors that make 
malaria infection the most common and potent trigger 
of VOC in SCD patients in malaria endemic countries. 
This  underscores  the  importance  of  continuous  life-
long  anti-malarial  prophylaxis  in  the  management  of 
SCD patients living in malaria endemic zones.
63 
 
Loffler’s  and  Tropical  Pulmonary  Eosinophilia 
Syndromes: The vast majority of patients with SCD 
live  in  tropical  and  under-developed  nations  of  the 
world  with  high  prevalence  of  protozoan  and 
helminthic infections that are related to poor personal 
and  environmental  sanitation  and  hygiene.  It  is 
therefore important to address the possible role of these 
infections with respect to VOC.  Nonetheless, there is 
paucity of literature with regards the role of intestinal 
parasites as co-morbid factors in patients with SCD in 
steady state and in the induction of VOC.  An isolated 
study    from  the  middle  east  had  demonstrated  that 
patients with SCD in steady state had relatively higher 
prevalence  of  protozoan  and  helminthic  intestinal 
parasites,  which  was  attributed  to  their  immune-
compromised  status.
66  A  solitary  uncontrolled  case-
study from Nigeria had reported high  prevalence of 
intestinal helminthic infections among SCD patients in 
VOC, suggesting a causal relationship.
67 But the study 
did not expound on the pathologic mechanisms through 
which the intestinal parasites could have triggered the 
VOC. 
 We infer that intestinal parasites may trigger VOC 
by  direct  affectation  of the  lungs  and  impairment  of 
oxygenation during the pulmonary migratory phase as 
seen in Loffler’s syndrome commonly associated with 
ascariasis and ancylostomiasis.
68,69 Loffler’s syndrome 
typically  presents  with  parasitic  and  eosinophilic 
pulmonary  infiltrates,  consolidations  and  reactive 
bronchospasm.
68,69  These  pathological  processes  that 
are associated with Loffler’s syndrome can eventually 
lead to a fall in PaO2, generalized hypoxia, increased 
red cell sickling, decreased pulmonary  conversion of 
deoxy-HbS to oxy-HbS, failure of reversal of sickled 
red cells to discocytes, piling of sickled cells and VOC. 
In addition, the peripheral blood eosinophilia, which is 
a regular accompaniment of Loffler’s  syndrome is also 
a  risk  factor  for  the  development  of  VOC  since 
activated eosinophils have been shown to adherence to 
vascular  endothelium  and  contribute  in  the 
pathogenesis of VOC.
70 
Filariasis  is  another  common  tropical  disease  that 
causes  Tropical  Pulmonary  Eosinophilia,  which  is 
characterized  by  microfilarial  pulmonary  infiltrates, 
bronchospasm and peripheral blood eosinophilia.
71 In 
similarity  to  Loffler’s  syndrome,  tropical  pulmonary 
eosinophilia can cause generalized hypoxia, increased 
red cell sickling with decreased pulmonary conversion 
of  deoxy-HbS  to  oxy-HbS,  failure  of  reversal  of 
sickled red cells and increased eosinophil adherence to Mediterr J Hematol Infect Dis 2011; 3: Open Journal System   
 
vascular  endothelium,  all  of  which  can  precipitate 
VOC. Hence, in parasite endemic zones, Loffler’s and 
tropical  pulmonary  eosinophilia  syndromes  must  be 
entertained  as  differential  diagnoses  in  SCD  patients 
presenting with clinical features of pneumonia, ACS or 
asthmatic episodes with or without VOC; and relevant 
stool,  skin  and  blood  tests  must  be  conducted  to 
confirm or rule them out. It is therefore rational to infer 
that  any  parasitic  infection  that  affects  the  lung  or 
causes  sustained  eosinophilic  change  in  the  lungs 
and/or the peripheral blood is a risk factor for VOC in 
patients with SCD.  
It is imperative that patients with SCD in parasites 
endemic  zones  should  be  regularly  subjected  to 
screening  tests  for  early  detection  and  treatment  of 
parasitic diseases during routine clinic visits.      
 
Mycoplasma Infection and Red Cell Auto-antibody: 
One of the most important atypical causative agent of 
ACS in patients with SCD is Mycoplasma pneumoniae, 
which  is  particularly  common  in  young  children.
72 
Mycoplasma  infection  can  be  complicated  by  the 
development  of  complement  fixing  IgM  anti-I  cold 
reacting  red  cell  auto-antibodies  that  can  cause 
agglutination and haemolysis in the colder peripheral 
parts  of  the  body.
73  More  over,  in  rare  cases 
mycoplasma  infection  maybe  associated  with  warm 
IgG  red  cell  auto-antibodies  that  can  cause 
agglutination  and  haemolysis  even  at  core  body 
temperature  of  37
oC.
74  Therefore,  SCD  patients  who 
develop  ACS  due  to  mycoplasma  are  at  risk  of 
developing  increased  haemolysis  if  the  infection  is 
associated with red cell auto-antibodies.
73 We infer that 
auto-agglutination  in  patients  with  SCD  will  also 
produce  large  red  cell  aggregates  that  would 
predictably  result  in  increased  blood  viscosity,  stasis 
and  impairment  of  blood  flow  leading  to  increased 
production of deoxy-HbS, red cell sickling and VOC. 
Auto-antibodies can also cause opsonization of sickled 
red  cell,  which  would  predictably  lead  to  increased 
adherence  of  opsonized  sickle  cells  to  Fc  and  C3 
complement  receptors  that  exist  on  membranes  of 
neutrophils.
75  This  adherence  effect  of  opsonins  will 
aggravate the well established role of neutrophil-sickle 
cell  interactions  in  VOC  as  reported  previously.
51,52 
Hence,  we  hypothetically    infer  that  red  cell  auto-
antibodies  would  increase  the  risk  of  VOC  in  SCD 
through the processes of agglutination (that increases 
viscosity) and opsonization (that increases sickled cell-
neutrophil adhesion).  
There is therefore the need for detailed studies to 
evaluate  the  incidence  of  auto-antibodies  and  their 
effect on rheology, sickling, opsonization, neutrophil-
sickle cell  adherence  and  vascular  occlusion in SCD 
patients  infected  by  mycoplasma.  Meanwhile,  it  is 
important to ensure that SCD patients with ACS and 
mycoplasma infection are promptly screened for cold 
and warm auto-agglutinins. While keeping the patients 
in warm environment will largely mitigate the effect of 
cold  antibodies,  cautious  administration  of  steroidal 
immunosuppressive agents maybe necessary to abolish 
the  production  of  warm  auto-antibodies  while  taking 
care  not  to  further  jeopardize  the  inherent  immune 
dysfunction due to the background SCD. 
 
Conclusion  and  Recommendation:  Infectious 
diseases have a multitude of proven and hypothetical 
mechanisms  through  which  they  can  cause  red  cell 
sickling  and  precipitate  VOC  in  patients  with  SCD. 
The role of infections in the pathogenesis of VOC is a 
particularly serious and challenging one in view of the 
background  immunodeficiency  associated  with  SCD 
and the high prevalence of infectious diseases in the 
underdeveloped countries within which most patients 
with  SCD  live.  It  is  therefore  imperative  for 
governmental  authorities  and  clinicians  in  countries 
with SCD to work concertedly to reduce the burden of 
infection on SCD patients. This can only be achieved 
through sustainable immunization programs, effective 
prophylactic  and  therapeutic  use  of  antimicrobial 
agents,  widespread use of barrier protections such as 
insecticide-treated mosquito nets and the introduction 
of environmental vector control measures for parasitic 
diseases. Poverty and illiteracy are also prevalent in the 
underdeveloped  nations  of  the  world.  Hence, 
eradication  of poverty  and  illiteracy,  as  enshrined  in 
the United Nations’ millennium development goals for 
underdeveloped countries, is a necessary requirement 
for  curtailing  the  high  prevalence  of  infection  and 
improving the quality of life of SCD sufferers in the 
long term. 
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